Viveve Medical

Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. It offers cryogen-cooled monopolar radio frequency technology, which delivered through a radiofrequency generator, hand piece and treatment tip. The Viveve system is a non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company was founded on March 3, 1987 and is headquartered Englewood, CO.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENGLEWOOD, CO / ACCESSWIRE /  December 17, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on December 16, 2020 that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Viveve is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.

Viveve Regains Compliance with NASDAQ Continued Listing Rules

Viveve Medical's (VIVE) CEO Scott Durbin on Q3 2020 Results - Earnings Call Transcript

Viveve Medical (VIVE) news for Tuesday includes positive results from a recent feasibility study pushing VIVE stock higher.
The post Viveve Medical News: Why VIVE Stock Is Rocketing 48% Today appeared first on InvestorPlace.

Viveve Medical News: Why VIVE Stock Is Rocketing 48% Today

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q2 2020 Results - Earnings Call Transcript

Avinger

Bioline RX

Proteostasis Therapeutics

Vaccinex Inc

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Bet on Rising Price-to-Earnings With 5 Top Stocks

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2020 Results - Earnings Call Transcript

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q4 2019 - Earnings Call Transcript

Viveve Medical, Inc (VIVE) CEO Scott Durbin on Q3 2019 - Earnings Call Transcript

Shave of Viveve Medical Inc. VIVE, -5.01% sank 11% toward a record low in premarket trading Friday, after the provider of health products and women's health services filed for the sale of new common stock to the public.

Viveve Medical stock plunges toward record low after filing to sell more shares

Viveve Medical's (VIVE) CEO Scott Durbin on Q2 2019 Results - Earnings Call Transcript

Viveve Medical (NASDAQ: VIVE) shares are trading lower after the company said its LIBERATE-International trial in SUI patients did not not achieve its primary endpoint.

Viveve Medical Shares Plummet After Trial Misses Primary Endpoint

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2019 Results - Earnings Call Transcript

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q4 2018 Results - Earnings Call Transcript

News for Viveve Medical Stock (VIVE)